(Sharecast News) - A treatment for a progressive eye disease that is being developed by a Sycona-backed company has delivered positive topline trial results, the life sciences investor confirmed on Monday, sending shares in the FTSE 250 firm sharply higher.
The gene therapy laru-zova is being developed by Beacon Therapeutics, a...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE